Crucell’s mission is to develop, produce and market vaccines worldwide to combat infectious and other diseases and to leverage its novel, proprietary technologies to develop monoclonal antibodies and therapeutic protein products.

Crucell’s strategy is to develop products that address currently unmet medical needs, particularly in relation to infectious diseases. We have a fully integrated infrastructure for in-house development, production and marketing of vaccines, and we are now leveraging our knowledge in this area to enter the proteins and antibodies market.

Our competitive edge lies in the strength of our proprietary technology platforms enabling us to produce high-value biotech products in the best possible way ― scalable and cost efficient. With our core technologies, such as PER.C6^®, we are well positioned to be a major player in the biotech arena, competing in a multi-billion dollar market.

Crucell's PER.C6® human cell line technology is ideally suited for the development and industrial-scale manufacturing of a wide range of biopharmaceuticals including vaccines, antibodies, therapeutic proteins and gene therapy products. Compared to conventional technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

Our business strategy is based on the following business drivers:

Leveraging presence of our marketed vaccines in public and private markets 

We have established products in hepatitis B, pediatric, respiratory and travel vaccines. We intend to enhance our position in these markets by highlighting the unique features of these products and by providing outstanding customer service in terms of delivery, reliability and quality, and by leveraging our worldwide presence in both public and private markets.

Product pipeline with competitive advantage  

We believe that each of our selected products either targets unmet medical needs, improves current medications, or is perceived as a marketable product due to predictive study models and/or due to perceived favorable regulatory conditions. We currently have four vaccine programs in clinical trials of which two are in Phase III or registration, and five vaccine programs and one antibody program in various stages of pre-clinical development, which are based on our PER.C6^® production technology. In addition, we have various discovery programs to find new vaccine, antibody and therapeutic protein leads.

Ongoing technology licensing program  

We have a broad base of excellent technologies with applicability for vaccines, antibodies, other recombinant proteins and gene therapy products. In areas where we are not developing our own products, we offer our technologies to the biopharmaceutical industry for the development and production of diverse biopharmaceutical products.

The ongoing and extensive PER.C6^® technology licensing program, and the as yet more limited licensing programs for our other technologies, support and accelerate our in-house product development. Our licensing program provides a source of revenue as well as the potential for future, additional revenue in the form of royalties from products developed by our licensees. We believe that our licensing program results in increased awareness in, and acceptance by, the biopharmaceutical industry and the regulatory authorities of our technology as a production technology for biopharmaceutical products.